A free diabetes, endocrinology and medical news article resource for endocrinologists and physicians. Endocrinology conference coverage and drug information.

2 天之前 · Phase 2 trial findings support empagliflozin use in patients without diabetes for calcium and uric acid stone prevention. Empagliflozin use can reduce the risk of calcium and uric acid …

5 天之前 · GLP 1 agonist use for diabetes and obesity may provide a range of benefits and risks not previously known.

2024年3月27日 · CGM use as an adjunct to GLP-1 therapy significantly improved HbA1c levels regardless of bolus insulin use among adults with type 2 diabetes.

2024年1月12日 · The 2024 Standards of Care includes revisions to incorporate person-first and inclusive language. Efforts were made to consistently apply terminology that empowers people …

2025年1月29日 · Use of GLP-1 receptor agonists reduced the risk of kidney failure and individual MACE components compared with placebo among patients with or without diabetes.

2025年1月29日 · The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Type 2 diabetes mellitus is a metabolic disorder characterized by dysregulation of blood glucose caused by relative insulin deficiency and insulin resistance. It is a progressive condition that …

2024年4月2日 · Addison disease — also referred to as primary adrenal insufficiency — occurs when the adrenal glands do not produce enough cortisol and/or aldosterone. Addison disease …

2024年6月14日 · The mechanism of action for GLP-1 agonists elicits different benefits for patients with diabetes and obesity.